XSHE
002326
Market cap2.30bUSD
Oct 09, Last price
17.19CNY
1D
3.49%
1Q
-14.09%
Jan 2017
18.11%
IPO
246.87%
Name
Zhejiang Yongtai Technology Co Ltd
Chart & performance
P/E
—
P/S
3.05
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.02%
Rev. gr., 5y
3.13%
Revenues
5.21b
+13.60%
Net income
-46m
L-90.36%
CFO
-72m
L-35.03%
Dividend
May 25, 20230.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Yongtai Technology Co., Ltd. engages in the production, research, development, sale, and service of medicines, pesticides, electronic chemicals, and new energy lithium battery materials. Its products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, advanced intermediates, basic intermediates, pesticides, liquid crystal materials, and lithium battery materials. It also provides contract manufacturing services. The company was founded by Ying Mei Wang and Ren Bao He on October 11, 1999 and is headquartered in Taizhou, China.
Key people
Yingmei Wang
Chairman of the Board · since 2007
Lijie Chen
Chief Financial Officer, Deputy General Manager, Director · since 2021
Jinfeng Huang
Deputy General Manager · since 2016
Yizhong Jin
Deputy General Manager, Director · since 2013
Chunhua Wang
Deputy General Manager · since 2016
Zichen Wang
Deputy General Manager · since 2019
Jiangshan Zhang
Deputy General Manager, Secretary of the Board · since 2018
Kuang He
General Manager, General Manager - Pharmaceutical Division, Director · since 2022
Lirong Wang
Chief Sales Officer, Director · since 2022
Hegeng Wei
Deputy General Manager, Director · since 2024
Zhiqiang Liu
Independent Director · since 2019
Weikun Zhang
Independent Director · since 2022
Independent Director · since 2023
Headquarters & legal address
浙江省化学原料药基地临海园区东海第五大道1号
台州市, ZJ 317016
CN
台州市, ZJ 317016
CN
Address
No.1, Donghai 5th Avenue，Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone
Taizhou, ZJ 317016
CN
Taizhou, ZJ 317016
CN
Other language
Zhejiang Yongtai Technology Co., Ltd
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||